Gilead to Acquire Genhouse in $1.5B+ Deal to Accelerate Synthetic Lethality

Deal Summary

Gilead Sciences announced a deal to acquire Genhouse for over $1.5 billion, aiming to strengthen its synthetic lethality oncology pipeline. The acquisition brings Genhouse’s portfolio of synthetic lethality drug candidates and technology into Gilead’s pipeline, underscoring its commitment to precision oncology.